Lantheus to acquire Evergreen Theragnostics for $250M upfront plus up to $752.5M in milestones

Lantheus Holdings, Inc.

Upfront cash consideration $250M; potential milestone payments up to $752.5M based on OCTEVY and pipeline products.
Evergreen adds radiopharmaceutical CDMO manufacturing infrastructure and registrational-stage NET diagnostic OCTEVY.
Transaction expected to close in second half of 2025, subject to regulatory clearances and customary conditions.
Lantheus reaffirms FY2024 revenue guidance of $1.51B-$1.52B and adjusted EPS of $6.65-$6.70.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.